Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease.
about
Octyl gallate markedly promotes anti-amyloidogenic processing of APP through estrogen receptor-mediated ADAM10 activationREVIEW: Curcumin and Alzheimer's DiseaseVitamin A and Alzheimer's diseaseHuman amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivoAmyloid beta-protein monomer folding: free-energy surfaces reveal alloform-specific differencesNSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivoγ-Secretase inhibitors and modulators.Inactivation of VCP/ter94 suppresses retinal pathology caused by misfolded rhodopsin in DrosophilaBrain intraventricular injection of amyloid-β in zebrafish embryo impairs cognition and increases tau phosphorylation, effects reversed by lithiumBeneficial effects of a pyrroloquinolinequinone-containing dietary formulation on motor deficiency, cognitive decline and mitochondrial dysfunction in a mouse model of Alzheimer's disease.Intracerebroventricular amyloid-beta antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 miceCystatin C-cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer's disease.Natural product extracts that reduce accumulation of the Alzheimer's amyloid beta peptide: selective reduction in A beta42.Efavirenz promotes β-secretase expression and increased Aβ1-40,42 via oxidative stress and reduced microglial phagocytosis: implications for HIV associated neurocognitive disorders (HAND).Inhibition of gamma-secretase as a therapeutic intervention for Alzheimer's disease: prospects, limitations and strategies.Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice.CD45RB is a novel molecular therapeutic target to inhibit Abeta peptide-induced microglial MAPK activation.A sensitive and selective electrochemical biosensor for the determination of beta-amyloid oligomer by inhibiting the peptide-triggered in situ assembly of silver nanoparticles.Altered proteolysis in fibroblasts of Alzheimer patients with predictive implications for subjects at risk of diseaseTargeting Abeta and tau in Alzheimer's disease, an early interim reportThe secretases: enzymes with therapeutic potential in Alzheimer disease.Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD miceAnti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model.Effects of age and amyloid deposition on Aβ dynamics in the human central nervous system.Plasma Abeta42 and Abeta40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study.Abeta42 is essential for parenchymal and vascular amyloid deposition in mice.Regulation of presynaptic Ca2+, synaptic plasticity and contextual fear conditioning by a N-terminal β-amyloid fragment.Anti-amyloidogenic and anti-apoptotic role of melatonin in Alzheimer diseaseImpact of sequence on the molecular assembly of short amyloid peptides.Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways.New developments in animal models of Alzheimer's disease.Regenerable and simultaneous surface plasmon resonance detection of aβ(1-40) and aβ(1-42) peptides in cerebrospinal fluids with signal amplification by streptavidin conjugated to an N-terminus-specific antibody.Alzheimer disease therapy: can the amyloid cascade be halted?The amyloid beta ion channel hypothesis of Alzheimer's disease.Synergistic interactions between Alzheimer's Aβ40 and Aβ42 on the surface of primary neurons revealed by single molecule microscopy.Physiologic and pathologic events mediated by intramembranous and juxtamembranous proteolysis.Caloric intake, dietary lifestyles, macronutrient composition, and alzheimer' disease dementiaIndependent relationship between amyloid precursor protein (APP) dimerization and γ-secretase processivity.Hologram QSAR models of a series of 6-arylquinazolin-4-amine inhibitors of a new Alzheimer's disease target: dual specificity tyrosine-phosphorylation-regulated kinase-1A enzyme.Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice
P2860
Q21132562-1252C7B0-B1E5-4FD2-86A4-8629AC533129Q22242293-07F1B8A3-84F6-4443-A34A-08AB1A8EC182Q22242414-373D1343-B145-4B72-9564-3F4DA1AD2EE3Q24603976-C32223D7-08ED-4C0A-9109-54BF2F1DA283Q24653927-B4132786-2A04-459F-BD28-0D64F7524B06Q24679444-DD4BA0B2-004A-407B-8751-9189D598C1F0Q26830462-8EE67C7A-FBDE-4341-8BC7-9BBA3EFB681DQ27346679-4617C314-9719-40DB-8CA7-D781B7285EC2Q28542815-4186BEDE-474D-49FA-B44B-930ABC4186D5Q30358683-952AEDA8-1594-4596-B167-D6C5578CDAF2Q30486176-49AD7F6D-D7B3-487F-B5AA-3D6D956F6B36Q30490690-CD7BDAFA-5D9E-408A-9612-D24A860B2A3BQ31108152-C41E4ED0-45BF-4AA2-81F9-1247005D7A02Q31159582-E993405D-A185-4C07-B977-B91ED9BECEDFQ33243260-820E418F-DA56-41D2-804D-83FA7DF8A4B0Q33291589-98E47727-C707-4655-A9CC-2F9E5C0DE4F1Q33334431-C46A82BE-862E-47A3-8CCF-FF9629577335Q33596318-F2A55BB4-E382-4736-9AB4-477AB3C28417Q33736357-C54274E2-A6E5-49A4-B872-47F9DF7170FAQ33829008-968DCD4B-17B5-46E1-A938-B88AD6B9B300Q33887222-0EA76197-8935-4907-927B-2FBD20DC7B3EQ33926242-71B98971-042E-4743-8498-607BC09C2D1AQ34195981-E6BEE059-E169-4CD1-A2ED-BA5D4B90748AQ34215733-81952288-7CFE-43DA-9613-C34A28245ED6Q34292024-30A13AD3-4FF1-427C-8A20-9389340996A3Q34374693-1CC89416-4295-46A9-A994-0BBD2690716FQ34383395-500FA57A-EB47-4A77-BB94-84F7933C4A7FQ34402167-12C28FAD-B0B3-4AF8-A5F2-61F8A2F0C9F9Q34442775-64DB74C2-4B9F-4D87-B072-94DE41770767Q34468169-66D0B755-08AE-4A69-9DE1-E5C939175880Q34566571-E33DED61-A682-4981-B7F7-ED3E0FA89771Q34768827-DEC353A7-A3A0-4524-B26D-E8DBF4C5C91FQ34828328-28966812-B00F-48DC-B579-1572D96C9E62Q34965996-1AE00439-2131-4913-B362-1D8628319309Q35061472-76C695D1-8F67-47EF-A8C2-D10DBE9C2345Q35079442-96ADA0B5-63B7-4EA0-9F8D-123EC1141322Q35130936-D5CB768A-024C-451E-91F7-B177BB69E444Q35371482-7F6F63A7-9DE2-45A2-AE5D-B43E640DEB4FQ35380915-826775EE-CF0F-467E-9972-F11AC92ED4C7Q35747037-4D4642CC-2B48-4AB7-ADD5-996A5BE3A65A
P2860
Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Biochemical detection of Abeta ...... atment of Alzheimer's disease.
@ast
Biochemical detection of Abeta ...... atment of Alzheimer's disease.
@en
type
label
Biochemical detection of Abeta ...... atment of Alzheimer's disease.
@ast
Biochemical detection of Abeta ...... atment of Alzheimer's disease.
@en
prefLabel
Biochemical detection of Abeta ...... atment of Alzheimer's disease.
@ast
Biochemical detection of Abeta ...... atment of Alzheimer's disease.
@en
P2093
P1476
Biochemical detection of Abeta ...... atment of Alzheimer's disease.
@en
P2093
C B Eckman
S G Younkin
P304
P356
10.1016/S0925-4439(00)00043-0
P407
P577
2000-07-01T00:00:00Z